West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded drugs — not be false or misleading,” contended Pharmaceutical Research and ...

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The stock has performed exceptionally well in recent years, driven by the success of its glucagon-like peptide-1 (GLP-1) receptor agonist drug portfolio ... comment about LLY in its Q3 2024 investor ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

WARNING ISSUED — A letter released this week shows that the FDA issued a warning last month to an outsourcing facility making compounded versions of popular GLP-1 medications to treat diabetes ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...